▶ 調査レポート

自家ワクチンのグローバル市場インサイト・予測(~2028年)

• 英文タイトル:Global Autogenous Vaccines Market Insights and Forecast to 2028

Global Autogenous Vaccines Market Insights and Forecast to 2028「自家ワクチンのグローバル市場インサイト・予測(~2028年)」(市場規模、市場予測)調査レポートです。• レポートコード:QY2203B10099
• 出版社/出版日:QYResearch / 2022年3月
• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥676,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,014,300 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,352,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界の自家ワクチンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に自家ワクチンの世界市場のxxx%を占める「家禽」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「大農場」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国の自家ワクチンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの自家ワクチン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの自家ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

自家ワクチンのグローバル主要メーカーには、Boehringer Ingelheim、Vaxxinova、Zoetis、Ceva Biovac、Phibro、Elanco、AniCon Labor GmbH、Cambridge Technologies、AVICARE plus、Genova Labs、Addison Biological Laboratory、ACE Laboratory Services、Deltamune、Dyntec、Hygieia Biological Laboratoriesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

自家ワクチン市場は、種類と用途によって区分されます。世界の自家ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
家禽、魚、豚、牛、その他

【用途別セグメント】
大農場、小農場

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 自家ワクチン製品概要
- 種類別市場(家禽、魚、豚、牛、その他)
- 用途別市場(大農場、小農場)
- 調査の目的
・エグゼクティブサマリー
- 世界の自家ワクチン販売量予測2017-2028
- 世界の自家ワクチン売上予測2017-2028
- 自家ワクチンの地域別販売量
- 自家ワクチンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別自家ワクチン販売量
- 主要メーカー別自家ワクチン売上
- 主要メーカー別自家ワクチン価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(家禽、魚、豚、牛、その他)
- 自家ワクチンの種類別販売量
- 自家ワクチンの種類別売上
- 自家ワクチンの種類別価格
・用途別市場規模(大農場、小農場)
- 自家ワクチンの用途別販売量
- 自家ワクチンの用途別売上
- 自家ワクチンの用途別価格
・北米市場
- 北米の自家ワクチン市場規模(種類別、用途別)
- 主要国別の自家ワクチン市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの自家ワクチン市場規模(種類別、用途別)
- 主要国別の自家ワクチン市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の自家ワクチン市場規模(種類別、用途別)
- 主要国別の自家ワクチン市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の自家ワクチン市場規模(種類別、用途別)
- 主要国別の自家ワクチン市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの自家ワクチン市場規模(種類別、用途別)
- 主要国別の自家ワクチン市場規模(トルコ、サウジアラビア)
・企業情報
Boehringer Ingelheim、Vaxxinova、Zoetis、Ceva Biovac、Phibro、Elanco、AniCon Labor GmbH、Cambridge Technologies、AVICARE plus、Genova Labs、Addison Biological Laboratory、ACE Laboratory Services、Deltamune、Dyntec、Hygieia Biological Laboratories
・産業チェーン及び販売チャネル分析
- 自家ワクチンの産業チェーン分析
- 自家ワクチンの原材料
- 自家ワクチンの生産プロセス
- 自家ワクチンの販売及びマーケティング
- 自家ワクチンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 自家ワクチンの産業動向
- 自家ワクチンのマーケットドライバー
- 自家ワクチンの課題
- 自家ワクチンの阻害要因
・主な調査結果

Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines, which prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual. Generally, indications of autogenous vaccines include resistance of pathogenic microorganisms to antibiotic treatment, ineffective therapy or immune response and lack of commercial vaccines.
Market Analysis and Insights: Global Autogenous Vaccines Market
Due to the COVID-19 pandemic, the global Autogenous Vaccines market size is estimated to be worth US$ 453.7 million in 2022 and is forecast to a readjusted size of US$ 587.4 million by 2028 with a CAGR of 4.4% during the review period. Fully considering the economic change by this health crisis, Poultry accounting for % of the Autogenous Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Large Farms segment is altered to an % CAGR throughout this forecast period.
Global Autogenous Vaccines key players include Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, etc. Global top five manufacturers hold a share over 50%. America is the largest market, with a share about 45%, followed by Europe and Asia Pacific, total have a share over 50 percent. In terms of product, Poultry is the largest segment, with a share over 50%. And in terms of application, the largest application is Large Farms, followed by Small Farms.
Global Autogenous Vaccines Scope and Segment
Autogenous Vaccines market is segmented by Obejection and by Application. Players, stakeholders, and other participants in the global Autogenous Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Obejection and by Application for the period 2017-2028.
Segment by Obejection
Poultry
Fishes
Pigs & Cattle
Other
Segment by Application
Large Farms
Small Farms
By Company
Boehringer Ingelheim
Vaxxinova
Zoetis
Ceva Biovac
Phibro
Elanco
AniCon Labor GmbH
Cambridge Technologies
AVICARE plus
Genova Labs
Addison Biological Laboratory
ACE Laboratory Services
Deltamune
Dyntec
Hygieia Biological Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Autogenous Vaccines Product Introduction
1.2 Market by Obejection
1.2.1 Global Autogenous Vaccines Market Size Growth Rate by Obejection, 2017 VS 2021 VS 2028
1.2.2 Poultry
1.2.3 Fishes
1.2.4 Pigs & Cattle
1.2.5 Other
1.3 Market by Application
1.3.1 Global Autogenous Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Large Farms
1.3.3 Small Farms
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Autogenous Vaccines Sales Estimates and Forecasts 2017-2028
2.2 Global Autogenous Vaccines Revenue Estimates and Forecasts 2017-2028
2.3 Global Autogenous Vaccines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Autogenous Vaccines Sales by Region
2.4.1 Global Autogenous Vaccines Sales by Region (2017-2022)
2.4.2 Global Sales Autogenous Vaccines by Region (2023-2028)
2.5 Global Autogenous Vaccines Revenue by Region
2.5.1 Global Autogenous Vaccines Revenue by Region (2017-2022)
2.5.2 Global Autogenous Vaccines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Autogenous Vaccines Sales by Manufacturers
3.1.1 Global Top Autogenous Vaccines Manufacturers by Sales (2017-2022)
3.1.2 Global Autogenous Vaccines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Autogenous Vaccines in 2021
3.2 Global Autogenous Vaccines Revenue by Manufacturers
3.2.1 Global Autogenous Vaccines Revenue by Manufacturers (2017-2022)
3.2.2 Global Autogenous Vaccines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Autogenous Vaccines Revenue in 2021
3.3 Global Autogenous Vaccines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Autogenous Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Autogenous Vaccines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Obejection
4.1 Global Autogenous Vaccines Sales by Obejection
4.1.1 Global Autogenous Vaccines Historical Sales by Obejection (2017-2022)
4.1.2 Global Autogenous Vaccines Forecasted Sales by Obejection (2023-2028)
4.1.3 Global Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
4.2 Global Autogenous Vaccines Revenue by Obejection
4.2.1 Global Autogenous Vaccines Historical Revenue by Obejection (2017-2022)
4.2.2 Global Autogenous Vaccines Forecasted Revenue by Obejection (2023-2028)
4.2.3 Global Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
4.3 Global Autogenous Vaccines Price by Obejection
4.3.1 Global Autogenous Vaccines Price by Obejection (2017-2022)
4.3.2 Global Autogenous Vaccines Price Forecast by Obejection (2023-2028)
5 Market Size by Application
5.1 Global Autogenous Vaccines Sales by Application
5.1.1 Global Autogenous Vaccines Historical Sales by Application (2017-2022)
5.1.2 Global Autogenous Vaccines Forecasted Sales by Application (2023-2028)
5.1.3 Global Autogenous Vaccines Sales Market Share by Application (2017-2028)
5.2 Global Autogenous Vaccines Revenue by Application
5.2.1 Global Autogenous Vaccines Historical Revenue by Application (2017-2022)
5.2.2 Global Autogenous Vaccines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Autogenous Vaccines Revenue Market Share by Application (2017-2028)
5.3 Global Autogenous Vaccines Price by Application
5.3.1 Global Autogenous Vaccines Price by Application (2017-2022)
5.3.2 Global Autogenous Vaccines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Autogenous Vaccines Market Size by Obejection
6.1.1 North America Autogenous Vaccines Sales by Obejection (2017-2028)
6.1.2 North America Autogenous Vaccines Revenue by Obejection (2017-2028)
6.2 North America Autogenous Vaccines Market Size by Application
6.2.1 North America Autogenous Vaccines Sales by Application (2017-2028)
6.2.2 North America Autogenous Vaccines Revenue by Application (2017-2028)
6.3 North America Autogenous Vaccines Market Size by Country
6.3.1 North America Autogenous Vaccines Sales by Country (2017-2028)
6.3.2 North America Autogenous Vaccines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Autogenous Vaccines Market Size by Obejection
7.1.1 Europe Autogenous Vaccines Sales by Obejection (2017-2028)
7.1.2 Europe Autogenous Vaccines Revenue by Obejection (2017-2028)
7.2 Europe Autogenous Vaccines Market Size by Application
7.2.1 Europe Autogenous Vaccines Sales by Application (2017-2028)
7.2.2 Europe Autogenous Vaccines Revenue by Application (2017-2028)
7.3 Europe Autogenous Vaccines Market Size by Country
7.3.1 Europe Autogenous Vaccines Sales by Country (2017-2028)
7.3.2 Europe Autogenous Vaccines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Autogenous Vaccines Market Size by Obejection
8.1.1 Asia Pacific Autogenous Vaccines Sales by Obejection (2017-2028)
8.1.2 Asia Pacific Autogenous Vaccines Revenue by Obejection (2017-2028)
8.2 Asia Pacific Autogenous Vaccines Market Size by Application
8.2.1 Asia Pacific Autogenous Vaccines Sales by Application (2017-2028)
8.2.2 Asia Pacific Autogenous Vaccines Revenue by Application (2017-2028)
8.3 Asia Pacific Autogenous Vaccines Market Size by Region
8.3.1 Asia Pacific Autogenous Vaccines Sales by Region (2017-2028)
8.3.2 Asia Pacific Autogenous Vaccines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Autogenous Vaccines Market Size by Obejection
9.1.1 Latin America Autogenous Vaccines Sales by Obejection (2017-2028)
9.1.2 Latin America Autogenous Vaccines Revenue by Obejection (2017-2028)
9.2 Latin America Autogenous Vaccines Market Size by Application
9.2.1 Latin America Autogenous Vaccines Sales by Application (2017-2028)
9.2.2 Latin America Autogenous Vaccines Revenue by Application (2017-2028)
9.3 Latin America Autogenous Vaccines Market Size by Country
9.3.1 Latin America Autogenous Vaccines Sales by Country (2017-2028)
9.3.2 Latin America Autogenous Vaccines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Autogenous Vaccines Market Size by Obejection
10.1.1 Middle East and Africa Autogenous Vaccines Sales by Obejection (2017-2028)
10.1.2 Middle East and Africa Autogenous Vaccines Revenue by Obejection (2017-2028)
10.2 Middle East and Africa Autogenous Vaccines Market Size by Application
10.2.1 Middle East and Africa Autogenous Vaccines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Autogenous Vaccines Revenue by Application (2017-2028)
10.3 Middle East and Africa Autogenous Vaccines Market Size by Country
10.3.1 Middle East and Africa Autogenous Vaccines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Autogenous Vaccines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Overview
11.1.3 Boehringer Ingelheim Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Boehringer Ingelheim Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Vaxxinova
11.2.1 Vaxxinova Corporation Information
11.2.2 Vaxxinova Overview
11.2.3 Vaxxinova Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Vaxxinova Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Vaxxinova Recent Developments
11.3 Zoetis
11.3.1 Zoetis Corporation Information
11.3.2 Zoetis Overview
11.3.3 Zoetis Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Zoetis Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Zoetis Recent Developments
11.4 Ceva Biovac
11.4.1 Ceva Biovac Corporation Information
11.4.2 Ceva Biovac Overview
11.4.3 Ceva Biovac Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Ceva Biovac Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ceva Biovac Recent Developments
11.5 Phibro
11.5.1 Phibro Corporation Information
11.5.2 Phibro Overview
11.5.3 Phibro Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Phibro Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Phibro Recent Developments
11.6 Elanco
11.6.1 Elanco Corporation Information
11.6.2 Elanco Overview
11.6.3 Elanco Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Elanco Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Elanco Recent Developments
11.7 AniCon Labor GmbH
11.7.1 AniCon Labor GmbH Corporation Information
11.7.2 AniCon Labor GmbH Overview
11.7.3 AniCon Labor GmbH Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AniCon Labor GmbH Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AniCon Labor GmbH Recent Developments
11.8 Cambridge Technologies
11.8.1 Cambridge Technologies Corporation Information
11.8.2 Cambridge Technologies Overview
11.8.3 Cambridge Technologies Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Cambridge Technologies Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cambridge Technologies Recent Developments
11.9 AVICARE plus
11.9.1 AVICARE plus Corporation Information
11.9.2 AVICARE plus Overview
11.9.3 AVICARE plus Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 AVICARE plus Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 AVICARE plus Recent Developments
11.10 Genova Labs
11.10.1 Genova Labs Corporation Information
11.10.2 Genova Labs Overview
11.10.3 Genova Labs Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Genova Labs Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Genova Labs Recent Developments
11.11 Addison Biological Laboratory
11.11.1 Addison Biological Laboratory Corporation Information
11.11.2 Addison Biological Laboratory Overview
11.11.3 Addison Biological Laboratory Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Addison Biological Laboratory Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Addison Biological Laboratory Recent Developments
11.12 ACE Laboratory Services
11.12.1 ACE Laboratory Services Corporation Information
11.12.2 ACE Laboratory Services Overview
11.12.3 ACE Laboratory Services Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 ACE Laboratory Services Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 ACE Laboratory Services Recent Developments
11.13 Deltamune
11.13.1 Deltamune Corporation Information
11.13.2 Deltamune Overview
11.13.3 Deltamune Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Deltamune Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Deltamune Recent Developments
11.14 Dyntec
11.14.1 Dyntec Corporation Information
11.14.2 Dyntec Overview
11.14.3 Dyntec Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Dyntec Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Dyntec Recent Developments
11.15 Hygieia Biological Laboratories
11.15.1 Hygieia Biological Laboratories Corporation Information
11.15.2 Hygieia Biological Laboratories Overview
11.15.3 Hygieia Biological Laboratories Autogenous Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Hygieia Biological Laboratories Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Hygieia Biological Laboratories Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Autogenous Vaccines Industry Chain Analysis
12.2 Autogenous Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Autogenous Vaccines Production Mode & Process
12.4 Autogenous Vaccines Sales and Marketing
12.4.1 Autogenous Vaccines Sales Channels
12.4.2 Autogenous Vaccines Distributors
12.5 Autogenous Vaccines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Autogenous Vaccines Industry Trends
13.2 Autogenous Vaccines Market Drivers
13.3 Autogenous Vaccines Market Challenges
13.4 Autogenous Vaccines Market Restraints
14 Key Findings in The Global Autogenous Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Autogenous Vaccines Market Size Growth Rate by Obejection, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Poultry
Table 3. Major Manufacturers of Fishes
Table 4. Major Manufacturers of Pigs & Cattle
Table 5. Major Manufacturers of Other
Table 6. Global Autogenous Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Autogenous Vaccines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Autogenous Vaccines Sales by Region (2017-2022) & (M Does)
Table 9. Global Autogenous Vaccines Sales Market Share by Region (2017-2022)
Table 10. Global Autogenous Vaccines Sales by Region (2023-2028) & (M Does)
Table 11. Global Autogenous Vaccines Sales Market Share by Region (2023-2028)
Table 12. Global Autogenous Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Autogenous Vaccines Revenue Market Share by Region (2017-2022)
Table 14. Global Autogenous Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Autogenous Vaccines Revenue Market Share by Region (2023-2028)
Table 16. Global Autogenous Vaccines Sales by Manufacturers (2017-2022) & (M Does)
Table 17. Global Autogenous Vaccines Sales Share by Manufacturers (2017-2022)
Table 18. Global Autogenous Vaccines Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Autogenous Vaccines Revenue Share by Manufacturers (2017-2022)
Table 20. Autogenous Vaccines Price by Manufacturers (2017-2022) &(US$/Does)
Table 21. Global Autogenous Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Autogenous Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autogenous Vaccines as of 2021)
Table 23. Autogenous Vaccines Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Autogenous Vaccines Product Offered
Table 25. Date of Manufacturers Enter into Autogenous Vaccines Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 28. Global Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 29. Global Autogenous Vaccines Sales Share by Obejection (2017-2022)
Table 30. Global Autogenous Vaccines Sales Share by Obejection (2023-2028)
Table 31. Global Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 32. Global Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 33. Global Autogenous Vaccines Revenue Share by Obejection (2017-2022)
Table 34. Global Autogenous Vaccines Revenue Share by Obejection (2023-2028)
Table 35. Autogenous Vaccines Price by Obejection (2017-2022) & (US$/Does)
Table 36. Global Autogenous Vaccines Price Forecast by Obejection (2023-2028) & (US$/Does)
Table 37. Global Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 38. Global Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 39. Global Autogenous Vaccines Sales Share by Application (2017-2022)
Table 40. Global Autogenous Vaccines Sales Share by Application (2023-2028)
Table 41. Global Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Autogenous Vaccines Revenue Share by Application (2017-2022)
Table 44. Global Autogenous Vaccines Revenue Share by Application (2023-2028)
Table 45. Autogenous Vaccines Price by Application (2017-2022) & (US$/Does)
Table 46. Global Autogenous Vaccines Price Forecast by Application (2023-2028) & (US$/Does)
Table 47. North America Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 48. North America Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 49. North America Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 50. North America Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 51. North America Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 52. North America Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 53. North America Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Autogenous Vaccines Sales by Country (2017-2022) & (M Does)
Table 56. North America Autogenous Vaccines Sales by Country (2023-2028) & (M Does)
Table 57. North America Autogenous Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Autogenous Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 60. Europe Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 61. Europe Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 62. Europe Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 63. Europe Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 64. Europe Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 65. Europe Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Autogenous Vaccines Sales by Country (2017-2022) & (M Does)
Table 68. Europe Autogenous Vaccines Sales by Country (2023-2028) & (M Does)
Table 69. Europe Autogenous Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Autogenous Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 72. Asia Pacific Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 73. Asia Pacific Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 74. Asia Pacific Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 75. Asia Pacific Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 76. Asia Pacific Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 77. Asia Pacific Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Autogenous Vaccines Sales by Region (2017-2022) & (M Does)
Table 80. Asia Pacific Autogenous Vaccines Sales by Region (2023-2028) & (M Does)
Table 81. Asia Pacific Autogenous Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Autogenous Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 84. Latin America Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 85. Latin America Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 86. Latin America Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 87. Latin America Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 88. Latin America Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 89. Latin America Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Autogenous Vaccines Sales by Country (2017-2022) & (M Does)
Table 92. Latin America Autogenous Vaccines Sales by Country (2023-2028) & (M Does)
Table 93. Latin America Autogenous Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Autogenous Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Autogenous Vaccines Sales by Obejection (2017-2022) & (M Does)
Table 96. Middle East and Africa Autogenous Vaccines Sales by Obejection (2023-2028) & (M Does)
Table 97. Middle East and Africa Autogenous Vaccines Revenue by Obejection (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Autogenous Vaccines Revenue by Obejection (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Autogenous Vaccines Sales by Application (2017-2022) & (M Does)
Table 100. Middle East and Africa Autogenous Vaccines Sales by Application (2023-2028) & (M Does)
Table 101. Middle East and Africa Autogenous Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Autogenous Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Autogenous Vaccines Sales by Country (2017-2022) & (M Does)
Table 104. Middle East and Africa Autogenous Vaccines Sales by Country (2023-2028) & (M Does)
Table 105. Middle East and Africa Autogenous Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Autogenous Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 107. Boehringer Ingelheim Corporation Information
Table 108. Boehringer Ingelheim Description and Major Businesses
Table 109. Boehringer Ingelheim Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 110. Boehringer Ingelheim Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Boehringer Ingelheim Recent Developments
Table 112. Vaxxinova Corporation Information
Table 113. Vaxxinova Description and Major Businesses
Table 114. Vaxxinova Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 115. Vaxxinova Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Vaxxinova Recent Developments
Table 117. Zoetis Corporation Information
Table 118. Zoetis Description and Major Businesses
Table 119. Zoetis Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 120. Zoetis Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Zoetis Recent Developments
Table 122. Ceva Biovac Corporation Information
Table 123. Ceva Biovac Description and Major Businesses
Table 124. Ceva Biovac Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 125. Ceva Biovac Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Ceva Biovac Recent Developments
Table 127. Phibro Corporation Information
Table 128. Phibro Description and Major Businesses
Table 129. Phibro Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 130. Phibro Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Phibro Recent Developments
Table 132. Elanco Corporation Information
Table 133. Elanco Description and Major Businesses
Table 134. Elanco Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 135. Elanco Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Elanco Recent Developments
Table 137. AniCon Labor GmbH Corporation Information
Table 138. AniCon Labor GmbH Description and Major Businesses
Table 139. AniCon Labor GmbH Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 140. AniCon Labor GmbH Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. AniCon Labor GmbH Recent Developments
Table 142. Cambridge Technologies Corporation Information
Table 143. Cambridge Technologies Description and Major Businesses
Table 144. Cambridge Technologies Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 145. Cambridge Technologies Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Cambridge Technologies Recent Developments
Table 147. AVICARE plus Corporation Information
Table 148. AVICARE plus Description and Major Businesses
Table 149. AVICARE plus Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 150. AVICARE plus Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. AVICARE plus Recent Developments
Table 152. Genova Labs Corporation Information
Table 153. Genova Labs Description and Major Businesses
Table 154. Genova Labs Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 155. Genova Labs Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Genova Labs Recent Developments
Table 157. Addison Biological Laboratory Corporation Information
Table 158. Addison Biological Laboratory Description and Major Businesses
Table 159. Addison Biological Laboratory Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 160. Addison Biological Laboratory Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Addison Biological Laboratory Recent Developments
Table 162. ACE Laboratory Services Corporation Information
Table 163. ACE Laboratory Services Description and Major Businesses
Table 164. ACE Laboratory Services Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 165. ACE Laboratory Services Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. ACE Laboratory Services Recent Developments
Table 167. Deltamune Corporation Information
Table 168. Deltamune Description and Major Businesses
Table 169. Deltamune Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 170. Deltamune Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Deltamune Recent Developments
Table 172. Dyntec Corporation Information
Table 173. Dyntec Description and Major Businesses
Table 174. Dyntec Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 175. Dyntec Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Dyntec Recent Developments
Table 177. Hygieia Biological Laboratories Corporation Information
Table 178. Hygieia Biological Laboratories Description and Major Businesses
Table 179. Hygieia Biological Laboratories Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2017-2022)
Table 180. Hygieia Biological Laboratories Autogenous Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Hygieia Biological Laboratories Recent Developments
Table 182. Key Raw Materials Lists
Table 183. Raw Materials Key Suppliers Lists
Table 184. Autogenous Vaccines Distributors List
Table 185. Autogenous Vaccines Customers List
Table 186. Autogenous Vaccines Market Trends
Table 187. Autogenous Vaccines Market Drivers
Table 188. Autogenous Vaccines Market Challenges
Table 189. Autogenous Vaccines Market Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources
List of Figures
Figure 1. Autogenous Vaccines Product Picture
Figure 3. Global Autogenous Vaccines Market Share by Obejection in 2021 & 2028
Figure 3. Poultry Product Picture
Figure 4. Fishes Product Picture
Figure 5. Pigs & Cattle Product Picture
Figure 6. Other Product Picture
Figure 7. Global Autogenous Vaccines Market Share by Application in 2021 & 2028
Figure 8. Large Farms
Figure 9. Small Farms
Figure 10. Autogenous Vaccines Report Years Considered
Figure 11. Global Autogenous Vaccines Sales 2017-2028 (M Does)
Figure 12. Global Autogenous Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Autogenous Vaccines Revenue 2017-2028 (US$ Million)
Figure 14. Global Autogenous Vaccines Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Autogenous Vaccines Sales Market Share by Region (2017-2022)
Figure 16. Global Autogenous Vaccines Sales Market Share by Region (2023-2028)
Figure 17. North America Autogenous Vaccines Sales YoY (2017-2028) & (M Does)
Figure 18. North America Autogenous Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Autogenous Vaccines Sales YoY (2017-2028) & (M Does)
Figure 20. Europe Autogenous Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Autogenous Vaccines Sales YoY (2017-2028) & (M Does)
Figure 22. Asia-Pacific Autogenous Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Autogenous Vaccines Sales YoY (2017-2028) & (M Does)
Figure 24. Latin America Autogenous Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Autogenous Vaccines Sales YoY (2017-2028) & (M Does)
Figure 26. Middle East & Africa Autogenous Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Autogenous Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Autogenous Vaccines in the World: Market Share by Autogenous Vaccines Revenue in 2021
Figure 29. Global Autogenous Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 31. Global Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 32. Global Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 33. Global Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 34. North America Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 35. North America Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 36. North America Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 37. North America Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 38. North America Autogenous Vaccines Sales Share by Country (2017-2028)
Figure 39. North America Autogenous Vaccines Revenue Share by Country (2017-2028)
Figure 40. United States Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 43. Europe Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 44. Europe Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 45. Europe Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 46. Europe Autogenous Vaccines Sales Share by Country (2017-2028)
Figure 47. Europe Autogenous Vaccines Revenue Share by Country (2017-2028)
Figure 48. Germany Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 49. France Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 54. Asia Pacific Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 55. Asia Pacific Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Autogenous Vaccines Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Autogenous Vaccines Revenue Share by Region (2017-2028)
Figure 59. China Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 62. India Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 69. Latin America Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 70. Latin America Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 71. Latin America Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Autogenous Vaccines Sales Share by Country (2017-2028)
Figure 73. Latin America Autogenous Vaccines Revenue Share by Country (2017-2028)
Figure 74. Mexico Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Autogenous Vaccines Sales Market Share by Obejection (2017-2028)
Figure 78. Middle East and Africa Autogenous Vaccines Revenue Market Share by Obejection (2017-2028)
Figure 79. Middle East and Africa Autogenous Vaccines Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Autogenous Vaccines Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Autogenous Vaccines Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Autogenous Vaccines Revenue Share by Country (2017-2028)
Figure 83. Turkey Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Autogenous Vaccines Revenue (2017-2028) & (US$ Million)
Figure 86. Autogenous Vaccines Value Chain
Figure 87. Autogenous Vaccines Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed